Newsroom

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Antengene Announces Results for Full Year 2022 with Updates Highlighting a Revenue Reaching 5.6 Times the Previous Year and Accelerated Global Innovation

Antengene Enters into Partnership with Hansoh Pharma

Antengene doses first US patient in ATG-017 with nivolumab combination trial

Antengene's ATG-022 Phase I CLINCH Trial for Solid Tumor Treatment Receives IND Approval in China

China’s NMPA approves Antengene’s XPOVIO for DLBCL

Antengene Announces XPOVIO® National Health Insurance Service Approval for Reimbursement in South Korea

Antengene announces preclinical study results on PD-L1/4-1BB bispecific antibody ATG-101

Antengene Advances ATG-022 in Phase II CLINCH Study for Solid Tumors in China and Australia

Antengene Announces Participation in the H.C. Wainwright 26th Annual Global Investment Conference

Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Antengene Announces Participation in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Antengene To Present One Oral and Four Abstracts at ASCO 2024

Antengene Announces One Oral and Three Poster Presentations at ASCO 2024

Antengene Presents Four Preclinical Posters at AACR 2024

Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline

Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research

Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia

Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms

Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs

Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting

Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting

Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline

Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO® (selinexor) in the Mainland of China

Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States

Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

Antengene Announces NDA Submission for XPOVIO® in Indonesia

Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO

Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting

Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia

Antengene Announces Results for Full Year 2022 with Updates Highlighting a Revenue Reaching 5.6 Times the Previous Year and Accelerated Global Innovation

Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting

Antengene to Host Webcast on Full Year 2022 Financial Results on Tuesday, March 28, 2023

Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China

Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)

Antengene Announces NDA Submission for XPOVIO® in Macau,China, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

Antengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022 (Claudin 18.2 ADC) in Patients with Advanced or Metastatic Solid Tumors

Antengene Appoints Amily Zhang as its Chief Medical Officer

Oral Presentation on Antengene's Anti-CD24 Monoclonal Antibody ATG-031 Selected for SITC's Top 100 Abstracts

Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer

Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting

Antengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China

Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

Antengene to Host Research and Development Day on November 15th and 17th, 2022

Antengene Announces XPOVIO® Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA

Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

Antengene to Present at Upcoming Industry Conferences

Antengene’s ATG-101 Receives the NMPA’s IND Approval for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Study highlights Antengene's complementary focus on diseases with a higher prevalence in China

Antengene announces XPOVIO approved by Australia for multiple myeloma

Singapore Health Sciences Authority approves Antengene’s Xpovio to treat R/R MM & R/R DLBCL in three indications

Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma

Antengene Announces Interim 2022 Financial Results and Provides Corporate Update

Antengene obtaining Korean IND approval for ATG-008, a mTOR Kinase Dual-Targeted Inhibitor

Phase 2 clinical trial of ATG-010 as targeted therapy for advanced non-small-cell lung cancer initiated in China

Antengene Appoints Bo Shan as Chief Scientific Officer

Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin’s Lymphoma

Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

Celgene and Antengene Corporation Announced Long-term Collaboration and Celgene has Become Shareholder of Antengene

Antengene announces China manufacturing plant in Shaoxing, China

Antengene Corporation Attend Qiming Venture Partners CEO Summit

Antengene Corporation Secures $21M in Series A Financing Round Led by Qiming Venture Partners

Antengene Corporation Attend the 20th Annual CSCO Meeting

Antengene Corporation attended Drug Development Case Study Workshop held by CFDA

Antengene Corporation has submitted The Phase 2 Clinical Trial Application of ATG-008 to China, Taiwan and Korea

Antengene Corporation Announces TFDA Approval of IND Application for a Phase II Study of ATG-008, a Next Generation mTOR Inhibitor, in Patients with Late-stage Hepatocellular Carcinoma (HCC)

Dr. Yijun Yang and Dr. Bo Shan joined Antengene Corporation

Antengene and Karyopharm Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia

International Torch Study (ATG-008-HCC-001) Investigator Meeting held by Antengene

ATG-008, China’s first TORC1/2 dual-targeted inhibitor of the new generation, has obtained IND approval

Antengene obtaining Korean IND approval for ATG-008, a mTOR Kinase Dual-Targeted Inhibitor

Antengene Corporation’s Strategic Partner, Karyopharm Therapeutics, Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma

Antengene and WuXi STA announced a strategic cooperation in process R&D and manufacturing

Antengene launches patient enrollment for TORC1/2 dual-targeted inhibitor ATG-008 in Taiwan

Antengene Presents a Series of Reports on TORC1/TORC2 Dual-Targeted Inhibitor ATG-008 at the 21st Annual Meeting of Chinese Society of Clinical Oncology

Karyopharm，Antengene Corporation’s Strategic Partner, Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor （ATG-010）as a Treatment for Patients with Penta-Refractory Multiple Myeloma

Antengene publishes clinical data on ATG-010 (Selinexor) for the treatment of refractory and/or relapsed multiple myeloma and relapsed diffuse large B-cell lymphoma at the Annual Meeting of Chinese Society of Clinical Oncology

Antengene Corporation won the Project Support of “the 13th Five- Year National Major New Drug Development Project”

Antengene Corporation Raises $120 Million in Series B Financing

Antengene Team Standing Out as a Leader in Innovation and Entrepreneurship

ATG-010, China’s first Selective Inhibitor of Nuclear Export obtains IND approval for the treatment of multiple myeloma

Antengene Corporation Announces Establishment of U.S. Subsidiary and Collaboration with the Baruch S. Blumberg Institute

Strong alliance for finding a new treatment of liver cancer: Antengene cooperates with Junshi Biosciences to conduct clinical research on the combination therapy of ATG-008 and Toripalimab to treat advanced liver cancer

Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Latest Progress in the treatment of blood cancer with Selinexor, a selective inhibitor of nuclear export

Take the crown! — Antengene was awarded the first prize in the 8th China Innovation& Entrepreneurship Competition

News Flash! The PAK4/NAMPT Dual Target Oral Inhibitor, ATG-019, Passed the Review of Investigational New Drug (IND) by Taiwan, China

Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer

Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors

Antengene Presented a Keynote Speech at J.P. Morgan Conference

News Express! The Clinical Trial of ATG-010 for Peripheral T-cell Lymphoma and NK/T-cell Lymphoma Has Been Approved

Novel oral medication for diffuse large B-cell lymphoma! Another indication of XPOVIO®, a first-in-class nuclear export inhibitor, is expected to achieve accelerated approval

Phase 3 Clinical Study of Novel Selective Inhibitor of Nuclear Export Selinexor with New Combination Therapy for Multiple Myeloma Meets Primary Endpoint

Phase 2 clinical trial of ATG-010 as targeted therapy for advanced non-small-cell lung cancer initiated in China

Clinical trial of Antengene’s ATG-008 in combination with Junshi Biosciences’ Toripalimab for treatment of advanced solid tumors and hepatocellular carcinoma officially initiated

Phase 2 clinical trial of ATG-008 as targeted therapy for advanced non-small-cell lung cancer initiated in China

Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin’s Lymphoma

Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions

Antengene Announces First Patient Dosed in China Registration Trial of ATG-010 (selinexor) for Relapsed or Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets

Antengene Doses First Patient with ATG-008, a mTOR1/2 Dual-targeted Inhibitor, for Advanced Solid Tumors and Hepatocellular Carcinoma of the Clinical Trial with Junshi Biosciences’ Toripalimab

Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer

Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions

Antengene Appoints Former Celgene ANZ Medical Leader Dirk Hoenemann as Head of Medical Affairs in Asia Pacific Region & Early Clinical Development

Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization

Australian Therapeutic Goods Administration (TGA) Approves the First Phase I Trial of ATG-017 (ERK 1/2 inhibitor) for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies

Antengene Announces IND Approval by NMPA to Initiate a Phase II Clinical Trial of ATG-008 for the Treatment of Advanced Solid Tumors with Specific Genetic Alterations

Antengene Announces First Patient Dosed with ATG-010 (selinexor) for Relapsed or Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma

Antengene Announces First Patient Dosing in a Phase I Trial of ATG-017 in Advanced Solid Tumors and Hematological Malignancies in Australia

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

Antengene’s New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer

Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

Antengene Submits NDAs for XPOVIO® (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL

Antengene Announces Acceptance of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

Antengene Announces Collaboration with Applied BioMath, LLC for Systems Pharmacology Modeling in Oncology

Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM

Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia

Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL

Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer

Antengene to Present at the 39th Annual J.P. Morgan Healthcare Conference

Restore the core! Selinexor (ATG-010), a first-in-class drug for multiple myeloma, to be launched in Hainan Free Trade Port

Antengene Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM

Antengene Partners with SAP to Implement an Automated Digital Enterprise Management System

Antengene Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China’s NMPA

Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index

Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea

Antengene Included in the Shenzhen-Hong Kong Stock Connect

Antengene Announces Financial Results for Full Year 2020

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

Antengene Appoints Bo Shan as Chief Scientific Officer

Antengene Appoints Kevin Lynch as Chief Medical Officer

Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations

Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL

Treatment with Selinexor in Advanced Liposarcoma Demonstrates Clinically Important Reduction in Pain with Improved HRQoL Outcomes

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer

Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies

Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome

Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021

Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021

Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

Antengene’s Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS

Antengene Provides an Update on Its Latest Developments

Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)

Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies

Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

Antengene and MindRank AI Enter into Collaboration to Advance the Development of Difficult-to-Drug Molecular Targets

Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China

Antengene Selected as a Constituent of the FTSE Global Equity Index Series

Antengene Announces Up to HK$100 million Share Repurchase Program

Antengene Announces IND Submitted to U.S. FDA for Its PD-L1/4-1BB Bispecific Antibody ATG-101 in Solid Tumors and Non-Hodgkin Lymphoma

Antengene to Present Data of Its PD-L1/4-1BB Bispecific Antibody ATG-101 and ERK1/2 Inhibitor ATG-017 at SITC 2021

Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates

Antengene to Host its First R&D Days on November 16 and November 18, 2021

Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting

Antengene Announces IND Approval in China for the Phase I Study of ATG-101 for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

Antengene Announces XPOVIO® Regulatory Approval in Singapore

Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma

Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

Antengene’s Pivotal “MARCH” Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine

Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting

Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018

Antengene and XtalPi Announce AI-Driven R&D Collaboration

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo (nivolumab) in Advanced Solid Tumors

Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor (ATG-010) for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH)

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

Antengene Announces NDA Approval by NMPA for XPOVIO®, China’s First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma

Antengene Included in the MSCI Global Small Cap Indexes – MSCI China Index Constituent Stocks

Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021

Antengene to Release Preliminary Results of Phase 1b TOUCH Trial of Selinexor (ATG-010) for the Treatment of Peripheral T-Cell Lymphoma and NKT-Cell Lymphoma at the 2021

Antengene Announces IND Approval in China for a Phase I II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma

Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L14-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma

Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101

Antengene Announces Research Collaboration with Celularity

“Research collaboration and introduction of new drugs will continue in South Korea, regarded as an attractive market”

Domestic biopharmaceutical companies will have strong presence globally

Antengene to Participate in Three Upcoming Investor Conferences in May&June

Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

Antengene Announces Commercial Availability of XPOVIO® (Selinexor) Prescribed for the First Time Across Mainland China

Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

Antengene Announces First Patient Dosed in the Phase I II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

Antengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma